Floatz logo

GADOPENTETATE DIMEGLUMINE

Breast Cancer Diagnosis

National Taiwan University HospitalSmall moleculePhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

225 Active assets in the Breast Cancer Diagnosis cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 3BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB
TAMOXIFEN
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB

View all 50 →

Same molecule, other indications

GADOPENTETATE DIMEGLUMINE is also rated in:

Magnetic Resonance ImagingDormant
BB
Indicative ·
67 / 100
View asset →
Positron Emission TomographyDormant
B
Indicative ·
60 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →